The potential role of bisphosphonates in prostate cancer

Oades, Grenville; Coxon, Jonathan P.; Colston, Kay W.

doi:10.1038/sj.pcan.4500607

Cited by 50 publications

(27 citation statements)

References 86 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bisphosphonates are potent inhibitors of osteoclastic bone resorption [18] that have been widely studied for the prevention of bone-related morbidity in CRPC patients. Large phase III randomised trials conducted in the 1990s established bisphosphonates as part of the standard treatment of patients with bone metastases from breast cancer, multiple myeloma, and other solid tumours [19].…”

Section: Discussionmentioning

confidence: 99%

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

Rajpar¹,

Massard²,

Laplanche³

et al. 2010

Annals of Oncology

View full text Add to dashboard Cite

Background: In patients with bone metastases from castration-resistant prostate cancer (CRPC) not pretreated with a bisphosphonate elevated N-telopeptide of type I collagen (uNTx), a marker of bone resorption, predicts skeletalrelated events (SRE). The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid.Methods: From 2004 to 2007, 94 patients with bone metastases from CRPC receiving zoledronic acid for at least 2 months were screened for uNTx.Results: Median age was 66 years (range 46-88). Median serum prostate-specific antigen (PSA) was 66 ng/ml (0-3984) and median uNTx was 19 nmol/mM creatinine (3-489). During follow-up, 38 patients (40%) experienced an SRE. Median OS was 20 months [95% (CI) confidence interval 15-24). In the multivariate analysis, elevated uNTx [hazard ratio (HR) 2.2 (95% CI 1.2-4.0)], serum PSA [HR 2.8 (95% CI 1.6-5.1)], and ECOG performance status were the only independent prognostic factors for OS. Median OS was 12 months (10-16) and 25 months (21-34) in patients with uNTx ‡20 nmol/mM creatinine and in those with uNTx <20 nmol/mM creatinine, respectively. Conclusion:An elevated uNTx level is an independent prognostic factor for OS in patients with bone metastases from CRPC receiving a bisphosphonate.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

Rajpar¹,

Massard²,

Laplanche³

et al. 2010

Annals of Oncology

View full text Add to dashboard Cite

show abstract

“…There is evidence that osteoblastic metastasis also involves considerable osteolysis [46,47]. In prostate cancer patients with clinical osteoblastic lesions, blood and urinary levels of bone resorption markers are often elevated [48].…”

Section: Osteoblastic Bone Metastasismentioning

confidence: 99%

Mechanisms of cancer metastasis to the bone

Yin¹,

Pollock²,

Kelly³

2005

Cell Res

295

226

View full text Add to dashboard Cite

Some of the most common human cancers, including breast cancer, prostate cancer, and lung cancer, metastasize with avidity to bone. What is the basis for their preferential growth within the bone microenvironment? Bidirectional interactions between tumor cells and cells that make up bone result in a selective advantage for tumor growth and can lead to bone destruction or new bone matrix deposition. This review discusses our current understanding of the molecular components and mechanisms that are responsible for those interactions.

show abstract

“…Recently, there have been reports of direct antitumour effects of bisphosphonates that might contribute to their inhibitory effects on bone metastases [8,[62][63][64]. These are thought to comprise one or more signal-disruption mechanisms producing antiproliferative, antiinvasive and anti-angiogenic actions.…”

Section: Other Signal-blocking Strategies In Bone Metastatic Prostatementioning

confidence: 99%

Src as a therapeutic target in men with prostate cancer and bone metastases

Saad

2009

BJU International

View full text Add to dashboard Cite

and bone-signalling processes involved in prostate tumour progression, driving proliferation, survival, migration and transition to androgen-independent growth. It is also intimately involved in positively regulating osteoclast physiology. As such, this molecule represents an attractive target for managing progressing prostate cancer. Encouraging results have been obtained in preclinical and clinical studies using Src inhibitors like AZD0530 and dasatinib. Both compounds reduced markers of bone resorption, in patients with cancer and those with advanced castration-resistant prostate cancer, respectively. Moreover, because Src is central to many mechanisms thought to be responsible for the development of castration resistance, adding Src inhibitors to a treatment regimen might reverse this phenomenon. As a result, many Src inhibitors are in preclinical development. This review explores Src inhibition as a strategy for managing bone metastasis in prostate cancer, with a particular focus on targeting the critical osteoclastic response. Other emerging and novel approaches are also considered.

show abstract

The potential role of bisphosphonates in prostate cancer

Cited by 50 publications

References 86 publications

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

Mechanisms of cancer metastasis to the bone

Src as a therapeutic target in men with prostate cancer and bone metastases

Contact Info

Product

Resources

About